1932

There is no abstract available.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-102015-123106
2016-01-06
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/56/1/annurev-pharmtox-102015-123106.html?itemId=/content/journals/10.1146/annurev-pharmtox-102015-123106&mimeType=html&fmt=ahah

Literature Cited

  1. Mukherjee S. 1.  2010. The Emperor of All Maladies: A Biography of Cancer New York: Scribner
  2. Hanahan D, Weinberg RA. 2.  2011. Hallmarks of cancer: the next generation. Cell 144:646–74 [Google Scholar]
  3. Lazo JS, Sharlow ER. 3.  2016. Drugging undruggable molecular cancer targets. Annu. Rev. Pharmacol. Toxicol. 56:23–40 [Google Scholar]
  4. Tong R, Kohane DS. 4.  2016. New strategies in cancer nanomedicine. Annu. Rev. Pharmacol. Toxicol. 5641–57
  5. Gross G, Eshhar Z. 5.  2016. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu. Rev. Pharmacol. Toxicol. 5659–83
  6. Gottesman MM, Lavi O, Hall MD, Gillet JP. 6.  2016. Toward a better understanding of the complexity of cancer drug resistance. Annu. Rev. Pharmacol. Toxicol. 5685–102
  7. Bobbin ML, Rossi JJ. 7.  2016. RNA interference (RNAi)-based therapeutics: delivering on the promise?. Annu. Rev. Pharmacol. Toxicol. 56103–22
  8. Childs-Disney JL, Disney MD. 8.  2016. Approaches to validate and manipulate RNA targets with small molecules in cells. Annu. Rev. Pharmacol. Toxicol. 56123–40
  9. Martinez Molina D, Nordlund P. 9.  2016. The cellular thermal shift assay: a novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies. Annu. Rev. Pharmacol. Toxicol. 56141–61
  10. Porteus M. 10.  2016. Genome editing: a new approach to human therapeutics. Annu. Rev. Pharmacol. Toxicol. 56163–90
  11. Śledź P, Baumeister W. 11.  2016. Structure-driven developments of 26S proteasome inhibitors. Annu. Rev. Pharmacol. Toxicol. 56191–209
  12. Vaught J. 12.  2016. Biobanking comes of age: the transition to biospecimen science. Annu. Rev. Pharmacol. Toxicol. 56211–28
  13. Whitaker RM, Corum D, Beeson CC, Schnellmann RG. 13.  2016. Mitochondrial biogenesis as a pharmacological target: a new approach to acute and chronic diseases. Annu. Rev. Pharmacol. Toxicol. 56229–49
  14. Yueh MF, Tukey RH. 14.  2016. Triclosan: a widespread environmental toxicant with many biological effects. Annu. Rev. Pharmacol. Toxicol. 56251–72
/content/journals/10.1146/annurev-pharmtox-102015-123106
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error